Drug intelligence / Profile preview

ACT002

Development stage: Preclinical
Lead developer: Accendatech
Modality: Small Molecules

Overview

ACT002 is a small molecule drug under preclinical development, primarily investigated for the treatment of neoplasms, including pancreatic cancer. It is being developed by Accendatech. The drug is also being explored for potential use in digestive system disorders and endocrinology/metabolic diseases. While specific details about its mechanism of action are not publicly disclosed, it has been suggested to target cancer stem cells as part of its therapeutic approach[1][10].

Beyond the preview

Go deeper on ACT002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACT002.

Explore the full profile